Biotech underperformed: XBI (2.5%), BBC (3.0%) and NBI (1.5%) versus XLV (0.1%). Single names moved both ways: Inovio nearly tripled to $1.89 on Friday's after-hours Voceryq approval while Precigen fell ~26%, and Bright Minds sank on a partial clinical hold disclosed Monday morning.

Oil and AI pulled opposite ways: Brent fell 7.6% to $104.77 on signs of a US-Iran diplomatic track, lifting the Dow +0.4%, while an afternoon tech selloff (Marvell (12.7%) and Lumentum (18.6%) on their combination, Oracle (8.8%) on a $10B stock sale) erased an early 1.1% S&P gain. NDX (1.4%), S&P (0.5%), RUT (0.2%); ISM manufacturing 55.5 vs 54.5 expected; 10Y -3.5bp to 4.89% into today's midterms.

FDA accepted the BLA for ifezuntirgene inilparvovec (AMT-130) under accelerated approval with priority review, PDUFA 1 May 2027; the acceptance letter says FDA tentatively plans an advisory committee, date not set. The filing rests on 36-month Phase 1/2 data (51 patients dosed) versus a propensity-matched Enroll-HD external control; confirmatory trial ~200 patients, 2:1 vs standard of care, Total Functional Capacity at 36 months, US screening by year end.

Why it matters: An external-control filing gets argued in public. The BLA leans on 36-month Phase 1/2 data against a propensity-matched Enroll-HD comparator rather than a randomized arm, which is the evidence an advisory panel tends to pull apart: how patients were matched, who dropped out, and whether slowing on a composite scale is a functional benefit. Priority review on top of Breakthrough, RMAT and Fast Track tags says FDA wants to move; the planned adcomm says it wants cover. The agreed ~200-patient randomized confirmatory trial, with a 36-month TFC endpoint, matters as much as the date, because accelerated approvals now come with withdrawal risk. A clean panel would give other CNS gene therapies built on natural-history controls a template; a split vote reprices QURE into May.

Source: Endpoints

More: Fierce Biotech; uniQure release (8-K)

FDA granted accelerated approval to Voceryq, a DNA immunotherapy given with the CELLECTRA 5PSP device, to reduce surgical papilloma excisions in adults with recurrent respiratory papillomatosis (approved Fri 30 Oct, after the close). In RRP-001, 32 adults enrolled and 26 were in the efficacy population (3+ surgeries in the prior 12 months, median 4.5); complete response, meaning no excision through 12 months, was 7/26 (27%, 95% CI 12-48%). Product ships in ~60 days, full launch Q1 2027; confirmatory protocol due by year end.

Why it matters: A small label with a large read-through. Voceryq is Inovio's first approved product after years of DNA-platform setbacks, and the stock nearly tripled to $1.89 on Monday. The loser is Precigen: Papzimeos has had the RRP market to itself since its August 2025 approval and booked $74.7M of net sales in 1H26, most of the company's revenue, and PGEN fell ~26%. On paper the data gap is wide, a 27% complete response from 26 patients in a single-arm study. The commercial fight is about convenience, payer appetite for a second option and Inovio's ability to fund a launch from a standing start in Q1 2027. The confirmatory protocol, due by year end, is the regulatory overhang.

Source: Fierce Pharma

More: Inovio release (8-K); Stocktwits

Lonza signed a definitive agreement to buy five US CDMO sites from Merck KGaA, Darmstadt, at an enterprise value in the low- to mid-triple-digit millions of Swiss francs, in cash from balance sheet and existing facilities; close expected mid-2027. The sites are St. Louis (bioconjugates), Madison and Verona, WI (high-potency payload-linkers), Carlsbad, CA (viral vectors, aseptic fill-finish) and Indianapolis (LNPs, liposomes, PEGylated proteins), with ~1,100 staff; Lonza's US sites go from four to nine, and ~CHF250M of 2028 sales is expected.

Why it matters: This is a supply bet on antibody-drug conjugates. St. Louis and the two Wisconsin sites cover conjugation and high-potency payload-linkers, the capacity-constrained steps in ADC manufacturing. Carlsbad and Indianapolis add viral-vector and LNP work, a softer demand pocket after the gene-therapy pullback, which is why Lonza guides to a sub-group core EBITDA margin on ~CHF250M of 2028 sales and only reaches group margin by the mid-2030s. A price in the low-to-mid hundreds of millions of francs is modest for five running US sites and 1,100 staff. Lonza kept its 2026 outlook, buyback and BBB+ rating, so this is a bolt-on, not a stretch. Merck KGaA, for its part, exits US contract manufacturing.

Source: Endpoints

More: Pharmaceutical Technology; Investing.com

Karyopharm filed Chapter 11 in the Southern District of Texas with up to $55M of DIP financing from its secured lenders; a restructuring support agreement makes Ayrmid, which tried to buy bluebird, lead bidder for a merger with the reorganised company, with close targeted for 1Q27. — Fierce Pharma

Novartis walked away from its ~$800M BrainTransporter neuroscience collaboration with BioArctic just 14 months after signing it. — Fierce Biotech

Teva stopped the Phase 2 TOPAS-MSA trial of emrusolmin (TEV-'286, 300 mg vs placebo, ~350 planned) in multiple system atrophy after a prespecified interim futility analysis; no safety concerns, and the broader programme is under review. — Fierce Biotech

Bright Minds' seizure candidate BMB-101 hit a partial FDA hold after preclinical mouse toxicity and concerns about its preparations for enrolling children. — Fierce Biotech

A DC federal judge ruled on 29 Oct that Botox must be excluded from Medicare price negotiation because its human serum albumin is plasma-derived, and barred HHS from publishing a maximum fair price for it. — Becker's

FDA inspection reports flagged sterilization issues at a Hansoh Pharma facility and data falsification at a Samsung Biologics site. — Fierce Pharma

Sun Pharma halted eye-care production at an India plant after a recall and quality findings. — BioSpace

Lonza / Merck KGaA — five US CDMO sites, EV low- to mid-triple-digit CHF millions, cash, close mid-2027. — Endpoints

Rhythm / LG Chem — bivamelagon licence amended: Rhythm pays $350M in fixed instalments through 2029 ($70M now) to replace a low-to-mid-single-digit royalty with 1% on its whole MC4R portfolio from 2029, plus up to $200M more at $3B annual sales; alongside, a new up to $750M term loan ($500M committed, SOFR+4.60%) led by HealthCare Royalty with Blackstone. — GlobeNewswire

AbbVie / Brise Pharmaceuticals (Beijing) — global licence to two preclinical migraine programmes, up to $757M; signed in 2024, disclosed Monday. — Endpoints

Fresenius / WuXi Biologics — biosimilars deal for up to 37 WuXi assets, taking Fresenius' portfolio to as many as 66 molecules aimed at an originator market of over €370B ($415B). — Fierce Pharma

Teva / Samsung Bioepis — US commercialisation rights to Enbrel biosimilar Eticovo at closing and infliximab-abda (Remicade) from Q3 2027; upfront paid over three years, launch and sales milestones, profit share; close by YE26. — GlobeNewswire

Biossil Labs / Theriva — buys SYN-004 (ribaxamase) and related antibiotic-degrading enzymes, $0.35M upfront, up to $91M milestones, low-single-digit royalties capped at $250M; Biossil's second asset buy after Alligator's mitazalimab (tracked Monday). — Fierce Biotech

CinRx / Graviton Bioscience — CinRock JV to develop ROCK2 inhibitors in PAH and HFpEF; terms undisclosed. — Endpoints

Specific Biologics (Toronto) — $35M oversubscribed Series A, led by Hatteras Venture Partners, joined by Lumira Ventures, adMare BioInnovations, Genesys Capital and BDC's Life Sciences Venture Fund; Dualase gene editor for C9ORF72 ALS into an adaptive Phase 1/2. — BioSpace

No notable IPOs or follow-ons since yesterday's edition.

Global cervical cancer burden reached 887,000 new cases and 369,000 deaths in 2023, with increases forecast by 2050. — Nature Medicine

The phase 2 UNICORN trial said neoadjuvant botensilimab with or without balstilimab met its primary response endpoint in colon cancer. — Nature Medicine

Povorcitinib beat placebo on F-VASI75 in the phase 3 STOP-V1 and STOP-V2 vitiligo trials. — Nature Medicine